Adding foam-roller self-myofascial release to an exercise program for people with type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial will compare an eight-week supervised exercise program alone versus the same program plus self-myofascial release applied with a foam roller to the plantar fascia and gastrosoleus muscles. Both groups will attend supervised sessions three times per week and be encouraged to perform at least 150 minutes per week of moderate walking, with adherence tracked by an exercise diary. Outcomes measured before and after the intervention include the Foot Function Index, single-leg stance with eyes open and closed, Timed Up and Go, unilateral heel-rise test, gait performance, and plantar fascia thickness by ultrasonography. Eligible participants are adults 30–65 years with controlled type 2 diabetes who ambulate independently, while people with neuropathy, peripheral vascular disease, obesity (BMI >30), recent lower-limb surgery, plantar fasciitis, or foot ulcers are excluded.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals aged 30 to 65 years
* Diagnosed with type 2 diabetes mellitus for at least 1 year
* Controlled type 2 diabetes mellitus
* Able to ambulate independently without assistive devices

Exclusion Criteria:

* Severe pes planus or pes cavus defined by the Foot Posture Index-6 (FPI-6) (score ≥ +10 or ≤ -5)
* History of plantar fasciitis
* Plantar fascia ulceration
* Peripheral neuropathy
* Diagnosed peripheral vascular disease
* History of lower extremity surgery or fracture during last year
* Rheumatologic or connective tissue disorders affecting soft tissue properties
* Neurological or diagnosed cognitive disorders
* Pregnancy
* Other types of diabetes mellitus
* Obesity (BMI \> 30 kg/m²)
* Serious cardiopulmonary disorders, including heart failure, history of myocardial infarction, or severe chronic obstructive pulmonary disease or asthma

Where it's running

• Bakırçay University Çiğli Regional Education Hospital
  Izmir, İzmir, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Sümena HAREKET KARAKAYA, PT
• Email: SumenaHareket4@gmail.com
• Phone: +905397264665

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acute Blood Flow Restriction Walking in Type 2 Diabetes

  This study tests whether adding blood flow restriction to treadmill walking affects immune cells in adults with type 2 diabetes.

  Recruiting University of British Columbia · Kelowna, British Columbia · NCT07928531

• Continuous Glucose Monitoring in Type 2 Diabetes Not on Insulin

  This study tests whether using a continuous glucose monitoring system helps people with type 2 diabetes who aren’t using insulin to improve blood sugar control and quality of life.

  Recruiting Medical University of Bialystok · Bialystok · NCT07919236

• Differentiating heart disease in autoimmune vs. type 2 diabetes

  This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.

  Recruiting University of Roma La Sapienza · Rome, Roma · NCT07911007

• Lifestyle Metabotype Study B: Understanding Personalized Glucose Responses

  This study tests how lifestyle, metabolism, and brain energy use relate to each person’s blood sugar response after meals, across people with and without prediabetes or type 2 diabetes.

  Recruiting at 2 sites German Institute of Human Nutrition · Berlin and 1 other locations · NCT07888257

• Lifestyle Metabotype Study: How Daily Habits Shape Blood Sugar

  This observational study tests whether personal lifestyle and biological factors can predict how a person’s blood sugar responds after meals.

  Recruiting German Institute of Human Nutrition · Potsdam, Potsdam-Rehbrücke · NCT07868601

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.